Your generous year-end donation will be matched $1 for $1 DONATE
NCCS submitted comments to the Food and Drug Administration (FDA) on the Draft Guidance: Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs). We support the FDA’s efforts to develop a strong regulatory framework for LDTs and commend the agency for the open and transparent process it has pursued in developing the framework and receiving […]
Today, NCCS joined colleagues in the cancer community in submitting comments to the National Institutes of Health (NIH) on the Draft NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research. We commend the National Institutes of Health (NIH) for taking this step to reduce duplication and inefficiency in the initiation […]
In late December 2014, NCCS joined colleagues in the Cancer Leadership Council in submitting comments to the Department of Health and Human Services (HHS) regarding the proposed rule on notice of benefit and payment parameters for 2016. Many cancer survivors have purchased qualified health plans (QHPs) through the health insurance exchanges and their access to […]
Last week, NCCS joined colleagues in the Cancer Leadership Council (CLC) in submitting comments to the National Association of Insurance Commissioners (NAIC) on the Health Benefit Plan Network Access and Adequacy Model Act. The groups collectively commend the NAIC Regulatory Framework (B) Task Force for including provisions within the act that would offer patients some […]
Last week, NCCS submitted comments to the U.S. Food and Drug Administration (FDA) regarding the series of patient-focused drug development meetings that have been convened and the list of disease topic meetings scheduled for 2016-2017. In 2013, FDA convened a patient-focused drug development meeting related to lung cancer and has plans to convene a breast […]
The Food and Drug Administration Safety and Innovation Act (FDASIA) authorized a patient-focused drug development program, and in the years since enactment, the U.S. Food and Drug Administration (FDA) has implemented certain initiatives of the patient-focused program. In recent weeks, FDA has requested feedback regarding patient-focused activities to date and recommendations about future efforts and […]
Click here to view all of NCCS’ policy comments. Recently, NCCS submitted comments to the Center for Medicare and Medicaid Innovation on its proposed Oncology Care Model (OCM), an episode-based payment model that emphasizes care planning and coordination and cancer care system transformation. The OCM represents an important step forward in encouraging patient-centered cancer care, […]
Recently, NCCS joined colleagues in the Cancer Leadership Council (CLC) in submitting comments to the Centers for Medicare and Medicaid Services (CMS) on the 2015 Physician Fee Schedule, which governs payments to physicians for services provided to Medicare patients. NCCS and the CLC have applauded efforts by CMS to strengthen care planning and coordination through […]
The National Coalition for Cancer Survivorship (NCCS) commends the Food and Drug Administration (FDA) for taking critical steps to ensure that the promise of personalized cancer medicine is realized and that cancer patients can rest assured that they are receiving treatments consistent with their diagnoses. Today, FDA notified Congress that it will issue a draft […]
The United States House of Representatives’ Energy and Commerce Committee released a Call to Action and announced the 21st Century Cures initiative to analyze the discovery, development, and delivery of cures and propose policy solutions. Over the course of the initiative, which officially launched on June 1, 2014, the committee will issue a series of […]
Survivorship Champions is a program for all clinicians and researchers, both oncology and primary care, who are interested in improving survivorship care and primary care’s role in caring for cancer survivors.
The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.
NCCS represents the millions of Americans who share a common experience – living with, through and beyond a cancer diagnosis. By sharing your story of how you have been touched by cancer, you are supporting the national cancer survivorship movement.
Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action
National Coalition for Cancer Survivorship
8455 Colesville Road | Suite 930 | Silver Spring, MD 20910
info@canceradvocacy.org | (877) NCCS-YES
Privacy Policy | Terms and Conditions
Copyright © 1995-2024 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.
"*" indicates required fields
"*" indicates required fields
Be the first to hear about cancer policy and survivorship issues! Subscribe and receive the biweekly NCCS Health Care Roundup, invites to webinars and events, and more.
Founder
Northeast Regional Cancer Institute
“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”
—Karen M. Saunders
President, Northeast Regional Cancer Institute